Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern

Viruses. 2023 Jan 25;15(2):346. doi: 10.3390/v15020346.

Abstract

Rapid emergence of the SARS-CoV-2 variants has dampened the protective efficacy of existing authorized vaccines. Nanoparticle platforms offer a means to improve vaccine immunogenicity by presenting multiple copies of desired antigens in a repetitive manner which closely mimics natural infection. We have applied nanoparticle display combined with the SpyTag-SpyCatcher system to design encapsulin-mRBD, a nanoparticle vaccine displaying 180 copies of the monomeric SARS-CoV-2 spike receptor-binding domain (RBD). Here we show that encapsulin-mRBD is strongly antigenic and thermotolerant for long durations. After two immunizations, squalene-in-water emulsion (SWE)-adjuvanted encapsulin-mRBD in mice induces potent and comparable neutralizing antibody titers of 105 against wild-type (B.1), alpha, beta, and delta variants of concern. Sera also neutralizes the recent Omicron with appreciable neutralization titers, and significant neutralization is observed even after a single immunization.

Keywords: BA.4/5; Omicron; SWE adjuvant; SpyCatcher; SpyTag; encapsulin; negative stain; thermotolerant.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic
  • Animals
  • COVID-19* / prevention & control
  • Humans
  • Mice
  • Nanoparticles*
  • SARS-CoV-2 / genetics

Substances

  • Adjuvants, Immunologic

Supplementary concepts

  • SARS-CoV-2 variants